Carvedilol: A Novel Cardiovascular Drug with Multiple Actions

Cardiovascular Drug Reviews

Volumn 10, Issue 2, 1992, Pages 127-157

  Ruffolo, Robert R ^a   Boyle, Duane A ^a   Brooks, David P ^a   Feuerstein, Giora Z ^a   Venuti, Robert P ^a   Lukas, Mary Ann ^a   Poste, George ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Antihypertensive; Cardioprotection; Carvedilol; Organ protection; Renal protection; 1 Adrenoceptor antagonist; Adrenoceptor antagonist

Indexed keywords

21 [4 [5,6 BIS(DIETHYLAMINO) 2 PYRIDYL] 1 PIPERAZINYL] 16ALPHA METHYLPREGNA 1,4,9(11) TRIENE 3,20 DIONE; ALPHA 1 ADRENERGIC RECEPTOR; ATENOLOL; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; CELIPROLOL; CIMETIDINE; DIGOXIN; HYDROCHLOROTHIAZIDE; NIFEDIPINE; NITRENDIPINE; PINDOLOL; PROPRANOLOL; RIFAMPICIN; VASODILATOR AGENT; WARFARIN;

ANGINA PECTORIS; ANTIHYPERTENSIVE ACTIVITY; BRAIN PROTECTION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; HEART INFARCTION SIZE; HEART PROTECTION; HEMODYNAMICS; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PLASMA CLEARANCE; RECEPTOR BLOCKING; REVIEW; SOMNOLENCE; VASODILATATION; VERTIGO;

EID: 0026754564     PISSN: 08975957     EISSN: 15273466     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1992.tb00242.x     Document Type: Article

References (126)

1. Long‐term treatment with beta‐blockers after myocardial infarction
2. Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction
3. A randomized trial of low‐dose beta‐blockade therapy for idiopathic dilated cardiomyopathy
4. Some quantitative uses of drug antagonism
5. Practolol in acute myocardial infarction
6. Carvedilol: a new logic for the treatment of hypertension
7. Refining the logic of antihypertensive therapy: an International Symposium on Carvedilol
8. Secondary prevention after high‐risk acute myocardial infarction with low‐dose acebutolol
9. Dose‐proportional stereoselectivity of carvedilol pharmacokinetics
10. Cardioprotective effects of carvedilol, a novel β‐adrenoceptor antagonist with vasodilating properties, in anesthetized minipigs: comparison with propranolol
11. Decreased catecholamine sensitivity and beta‐adrenergic receptor density in failing human hearts
12. Limitation of myocardial infarct size by atenolol, nadolol and propranolol in dogs
13. Carvedilol
14. Clinical pharmacology of carvedilol in normal volunteers
15. Oral beta‐adrenergic blockade with metoprolol in chronic severe dilated cardiomyopathy
16. The effects of intravenous carvedilol: a new multiple action vasodilatory beta‐blocker in congestive heart failure
17. Value of carvedilol in congestive heart failure secondary to coronary artery disease
18. Comparison of antihypertensive efficacy of carvedilol, a new vasodilating β‐blocker, versus atenolol
19. Carvedilol increases the systemic bioavailability of oral digoxin
20. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension
21. Haemodynamic effects of carvedilol, a new beta‐adrenoceptor blocker and precapillary vasodilator in essential hypertension
22. Hemodynamic effects of combined beta‐adrenoceptor blockade and precapillary vasodilation in hypertension
23. Acute and long‐term hemodynamic effects of carvedilol, a combined beta‐adrenoceptor blocking and precapillary vasodilating agent, in hypertensive patients
24. Influence of carvedilol on blood glucose and glycohaemoglobin A1 in non‐insulin‐dependent diabetics
25. High‐performance liquid chromatographic method for the simultaneous determination of the enantiomers of carvedilol and its O‐desmethyl metabolite in human plasma after chiral derivatization
26. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double‐blind, randomized, placebo‐controlled trial
27. Myocardial protection by carvedilol
28. Stereoselective disposition and glucuronidation of carvedilol in healthy subjects [Abstract]
29. Assay and disposition of carvedilol enantiomers in humans and monkeys: evidence of stereoselective presystemic metabolism
30. Importance of the adrenergic nervous system in the support of circulatory function in patients with congestive heart failure
31. Effect of carvedilol and renal hemodynamics and renal excretory function in spontaneously hypertensive rat
32. Effects of carvedilol on serum lipids in patients with essential hypertension
33. Pharmacokinetics of carvedilol in hypertensive patients with renal failure
34. Pharmacokinetics of DQ‐2466 (carvedilol), a new beta‐adrenoceptor blocking agent, in healthy volunteers
35. Carvedilol, a new multiple action vasodilatory beta‐blocker for the management of essential hypertension: a comparison with slow‐release nifedipine and with atenolol
36. Carvedilol (Kredex) reduces infarct size in a canine model of acute myocardial infarction
37. One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial
38. Carvedilol for systemic hypertension
39. Effects of carvedilol on plasma hormonal and biochemical factors and renal function in Japanese patients with essential hypertension
40. Changes in glomerular filtration rate during long‐term treatment with propranolol in patients with arterial hypertension
41. Efficacy of carvedilol (BM 14.190), a new beta‐blocking drug with vasodilatory properties, in exercise‐induced myocardial ischemia
42. Evaluation of a new vasodilating beta‐blocking agent, carvedilol, in exertional angina using Holter monitoring
43. Blood pressure‐lowering effect of carvedilol vs. nitrendipine in geriatric hypertensives
44. Effects of carvedilol on cerebral blood flow and its autoregulation in previous stroke patients with hypertension
45. Effects of carvedilol in patients with impaired left ventricular function due to ischaemic heart disease
46. Comparison of effectiveness and safety of carvedilol (25 mg once daily) versus labetalol (200 mg twice daily) in patients with mild to moderate hypertension using an ambulatory 24 hours Holter monitoring [Abstract]
47. A multicenter comparison of carvedilol with hydrochlorothiazide in the treatment of mild to moderate essential hypertension
48. Resting and postexercise hemodynamic effects of carvedilol, a beta‐adrenergic blocker and precapillary vasodilator in hypertensive patients
49. A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report
50. Chronic hemodynamic effects of carvedilol in essential hypertension at rest and during exercise
51. Inhibition of sarcolemmal carbon centered free radicals formation by propranolol
52. Temporal relationships of free radical induced lipid peroxidation and loss of latent enzyme activity in highly enriched hepatic liposomes
53. Effects of metabolic and pharmacologic interventions on myocardial infarct size following coronary occlusion
54. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease. A review of randomized controlled trials
55. Effects of carvedilol on blood pressure in patients with mild to moderate hypertension
56. Circadian antihypertensive profile of carvedilol (BM 14190)
57. Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension
58. The effect of delay in propranolol administration on reduction of myocardial infarct size after experimental coronary artery occlusion in dogs
59. Effect of carvedilol and metoprolol on blood pressure, blood flow and vascular resistance
60. The use of carvedilol in elderly hypertensive patients
61. Improvement in prognosis of myocardial infarction by long‐term beta‐adrenoceptor blockade using practolol
62. Reduction in mortality after myocardial infarction with long‐term beta‐adrenergic blockade (supplementary report)
63. Effects of carvedilol on common carotid arterial flow, peripheral hemodynamics, and hemorheologic variables in hypertension
64. Effects of carvedilol on renal function and blood pressure in three‐fifths nephrectomized spontaneously hypertensive rats loaded with high salt
65. Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound
66. Pharmacokinetics and disposition of carvedilol in humans
67. Pharmacokinetics and bioavailability of carvedilol in patients with liver cirrhosis
68. Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol
69. The relationship of α‐adrenoceptor reserve and agonist intrinsic efficacy to calcium utilization in the vasculature
70. The interaction of the enantiomers of carvedilol with alpha 1‐ and beta 1‐adrenoceptors
71. In vitro pharmacologic profile of the novel β‐adrenoceptor antagonist and vasodilator, carvedilol
72. Timolol‐induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction
73. Safety and efficacy of once‐daily carvedilol vs. twice‐daily labetalol in mild to moderate hypertension
74. Smooth muscle cell hypertrophy versus hyperplasia in hypertension
75. Excitatory amino acids release and free radical formation may operate in the genesis of ischemia‐induced neuronal damage
76. Effect of propranolol on progression of chronic renal disease in partially nephrectomized rats
77. High‐performance liquid chromatographic method for the determination of carvedilol and its desmethyl metabolite in body fluids
78. On the nature of protection by propranolol against myocardial necrosis after temporary coronary occlusion in dogs
79. Digoxin
80. Response rate with respect to the blood pressure‐lowering effect of the vasodilating and β‐blocking agent carvedilol
81. Controlled double‐blind trial of nifedipine in the treatment of Raynaud's phenomena
82. Antianginal efficacy of carvedilol, a beta‐blocking drug with vasodilating activity
83. 1‐antagonist
84. Pharmacokinetic and pharmacodynamic interactions of combined acute administration of carvedilol and hydrochlorothiazide in hypertensive volunteers
85. Important concepts of receptor theory
86. Cardiovascular adrenoceplors: physiology and critical care implications
87. Carvedilol (Kredex): a novel multiple action cardiovascular agent
88. The pharmacology of carvedilol
89. Evaluation of a novel antihypertensive agent, LY127210, in anesthetized and conscious spontaneously hypertensive rats
90. Hemodynamic differences between carvedilol and labetalol in the cutaneous circulation
91. Efficacy and safety of carvedilol in the treatment of hypertension
92. Effects of carvedilol on serum lipids in hypertensive and normotensive subjects
93. Alpha‐ and beta‐adrenoceptor blocking action of carvedilol in the canine mesenteric artery and vein
94. Influence of carvedilol and propranolol on coronary blood flow
95. Controlled trial of nifedipine in the treatment of Raynaud's phenomenon
96. Cardioprotective effects of carvedilol in two models of myocardial infarction [Abstract]
97. Effect of propranolol on ischemic myocardial damage and left ventricular hypertrophy following permanent coronary artery occlusion or occlusion followed by reperfusion
98. Cardioprotective effects of the vasodilator/β‐adrenoceptor blocker, carvedilol, in two models of myocardial infarction in the rat
99. Pharmacological profile of carvedilol as a beta‐blocking agent with vasodilating and hypotensive properties
100. Studies on the mode of vasodilating action of carvedilol
101. Double‐blind controlled clinical trial to evaluate the antihypertensive effect of carvedilol in elderly patients with mild to moderate hypertension
102. Pharmacological profile of carvedilol, a compound with beta‐blocking and vasodilating properties
103. Vasodilatory effects of carvedilol and pindolol
104. Carvedilol inhibits vascular smooth muscle proliferation
105. Beneficial effects of long‐term beta‐blockade in congestive cardiomyopathy
106. Intersubject and intrasubject variability in the pharmacokinetics of carvedilol (SK ∓ F 105517, BM 14.190)
107. Haemodynamics of carvedilol in normal subjects compared with propranolol, pindolol, and labetalol
108. Carvedilol reduces myocardial damage caused by coronary occlusion in dogs [Abstract]
109. Treatment of chronic stable angina with carvedilol in comparison with nifedipine SR
110. Efficacy and safety of carvedilol in comparison with atenolol in hypertensive patients pretreated with hydrochlorothiazide
111. Liquid chromatographic assay and disposition of carvedilol in healthy volunteers
112. Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta‐blocker
113. Long‐term beta‐blockade in dilated cardiomyopathy. Effects of short‐ and long‐term metoprolol treatment followed by withdrawal and read‐ministration of metoprolol
114. Effect of chronic beta‐adrenergic receptor blockade in congestive cardiomyopathy
115. β‐Adrenergic receptor blockade and renal function
116. Renal effects of β‐adrenoceptor blockade
117. Safety and antihypertensive efficacy of carvedilol and atenolol alone and in combination with hydrochlorothiazide
118. Local cutaneous hemodynamic effects of carvedilol and labetalol in the anesthetized rat
119. Carvedilol, a new beta‐adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits oxygen radical mediated lipid peroxidation in swine ventricular membranes
120. Carvedilol, a new adrenoceptor antagonist and vasodilator antihypertensive drug, inhibits superoxide release from human neutrophils